Triple-negative breast cancer (TNBC) is described as highly heterogeneous due to the non-existence of canonical targets such as the estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and the progesterone receptor [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.